Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Prostate cancer (PC) is one of the most urgent problems of modern urologic oncology in Russia because of a steady rise in morbidity and mortality rates associated with this disease. Radical prostatectomy (RP) and external beam radiotherapy (EBRT) or brachytherapy are mainstay treatments in patients with localized and locally advanced PC. Just the same, the rate of lymphogenic disease progression after radical treatment is as high as 15–40 %. At the same time, a search for a tumor focus leading to an increase in the marker is extremely important. If a local recurrence is detected after previous RP, there may be salvage EBRT. After verifying the relapse after salvage EBRT or brachytherapy, RP may be recommended to patients in the specialized centers having appropriate experience with this type of surgery. In patients with distant metastases, palliative hormonal therapy has been the only conventional method so far. Nonetheless, in a considerable number of patients, a marker recurrence may be associated with the so-called oligometastatic progression of the disease, in which the number of detected metastatic foci is minimal. The clinical introduction of promising and precise diagnostic methods having high sensitivity and specificity even with the minimal levels of prostate-specific antigen, such as magnetic resonance imaging and positron tomography, could substantially increase the number of detectable patients with oligometastases and propose new therapeutic conceptions for the treatment of this contingent of patients. Recently, in the literature there have been increasingly more works suggesting the possibility of using local treatments (surgery or radiotherapy) in patients with oligometastases when the disease progresses after radical treatment. The results of investigations show that a personalized approach and surgical or radiation treatments in selected patients make it possible to increase survival prior to the use of hormonal treatment and, in a number of cases, to completely abandon the latter. The paper gives a review of the literature data dealing with this problem.

1. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013 (morbidity and fatality). Ed. by А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow, 2015. (In Russ.)].

2. Han M., Partin A.W., Pound C.R. et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555–65.

3. Simmons M.N., Stephenson A.J., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007;51(5):1175–84.

4. Suardi N., Porter C.R., Reuther A.M. et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112(6):1254–63.

5. Roehl K.A., Han M., Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910–4.

6. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7.

7. Lussier Y.A., Khodarev N.N., Regan K. et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific micro-RNA. PLoS One 2012;7(12):e50141.

8. Garcia J.R., Morenco C., Valls E. et al. Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol 2015;34(3):155–61.

9. von Eyben F.E., Kairemo K. Metaanalysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35(3): 221–30.

10. Gabriele D., Collura D., Oderda M. et al. Is there still a role of computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J Urol 2016;34(4):517–23.

11. Асланиди И.П., Пурсанова Д.М., Мухортова О.В. и др. ПЭТ/КТ с 11С-холином в диагностике рецидива рака предстательной железы у пациентов с биохимическим прогрессированием. Онкоурология 2015;11(3):79–86. DOI:10.17650/1726-9776-2015-11-3-79-86. [Aslanidi I.P., Pursanova D.M., Mukhortova O.V. et al. 11C-Choline PET/CT in the detection of prostate cancer relapse in patients with rising PSA. Onkourologiya = Cancer Urology 2015;11(3):79–86. (In Russ.). DOI:10.17650/1726-9776-2015-11-3-79-86].

12. Afshar-Oromieh A., Zechmann C.M., Malcher A. et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11–20. DOI: 10.1007/s00259-013-2525-5.

13. Власова О.П., Герман К.Э., Крылов В.В. и др. Новые радиофармпрепараты для диагностики и лечения метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник РАМН 2015;70(3):360–5. DOI: 10.15690/vramn. v70i3.1334. [Vlasovа О.P., German K.E., Krylov V.V. et al. New radiopharmaceuticals for the diagnostics and treatment of the prostate metastatic cancer on the basis of prostate specific membrane antigen. Vestnik RAMN = RAMS Herald 2015;70(3):360–5. DOI: 10.15690/vramn.v70i3.1334. (In Russ.)].

14. Долгушин М.Б., Оджарова А.А., Михайлов А.И. и др. ПЭТ/КТ с 18F-фторхолином в режиме двухэтапного сканирования при биохимических рецидивах рака предстательной железы. Онкоурология 2015;11(2):46–54. DOI: 10.17650/1726- 9776-2015-11-2-46-54. [Dolgushin M.B., Odzharova A.A., Mikhaylov A.I. et al. Dualstage 18F-fluorocholine PET/CT scanning for biochemical recurrences of prostate cancer. Onkourologiya = Cancer Urology 2015;11(2):46–54. (In Russ.). DOI: 10.17650/1726-9776-2015-11-2-46-54].

15. Tilki D., Reich O., Graser A. et al. 18FFluoroethylcholin PET/CT identifies lymph node metastasis in patients with prostatespecific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013;63(5):792–6.

16. Eiber M., Maurer T., Souvatzoglou M. et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015;56(5): 668–74. DOI: 10.2967/jnumed.115.154153.

17. Osborne J.R., Akhtar N.H., Vallabhajosula S. et al. Prostate-specific membrane antigenbased imaging. Urol Oncol 2013;31(2): 144–54. DOI: 10.1016/j.urolonc.2012.04.016.

18. Mease R.C., Foss C.A., Pomper M.G. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 2013;13(8):951–62.

19. Wetter A., Lipponer C., Nensa F. et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F] choline PET/CT. Eur J Nucl Med Mol Imaging 2014;41(1):79–88. DOI: 10.1007/s00259-013-2560-2.

20. Wu L.M., Xu J.R., Gu H.Y. et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol) 2013;25(4):252–64. DOI: 10.1016/j. clon.2012.11.010.

21. Abdollah F., Sun M., Thuret R. et al. Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. Eur Urol 2010;58(6):882– 92. DOI: 10.1016/j.eururo.2010.09.029.

22. Tilki D., Mandel P., Seeliger F. et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol 2015;193(2):484–90. DOI: 10.1016/j.juro.2014.08.096.

23. Rigatti P., Suardi N., Briganti A. et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline positron emission tomography/computed tomography. Eur Urol 2011;60(5):935–43. DOI: 10.1016/j. eururo.2011.07.060.

24. Winter A., Henke R.P., Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol 2015;15:10. DOI: 10.1186/s12894-015-0004-y.

25. Briganti A., Karnes J.R., Da Pozzo L.F. et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer: a new proposal based on a twoinstitution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55(2):261–70. DOI: 10.1016/j.eururo.2008.09.043.

26. Ji J., Yuan H., Wang L. et al. Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study. J Surg Res 2012;178(2):779–84. DOI: 10.1016/j. jss.2012.06.069.

27. Jilg C.A., Rischke H.C., Reske S.N. et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012;188(6):2190–7. DOI: 10.1016/j.juro.2012.08.041.

28. Suardi N., Karnes J., Joniau S. et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol 2013;189:e317–8.

29. Chao D.H., Higgins J.P., Brooks J.D. Biochemical remission after resection of prostate cancer lung metastasis. Urology 2004;63(3):584–5.

30. Pruthi R.S., Hubbard J.S., Kouba E., Wallen E. Androgen-independent prostate cancer treated with resection of the solitary metastatic site. Urol Int 2007;79(4):371–3.

31. Fattahi Masoum S.H., Feizzdeh Kerigh B., Goreifi A. Pulmonary and chest wall metastasectomy in urogenital tumors: a single center experience and review of literature. Nephrourol Mon 2014;6(3):e17258. DOI: 10.5812/numonthly.17258.

32. Gronau E., Goppelt M., Harzmann R. et al. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma. Onkologie 2005;28(6–7):361–6.

33. Jereczek-Fossa B.A., Beltramo G., Fariselli L. et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):889–97. DOI: 10.1016/j. ijrobp.2010.11.031.

34. Berkovic P., De Meerleer G., Delrue L. et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013;11(1):27–32. DOI: 10.1016/j. clgc.2012.08.003.

35. Bhattasali O., Chen L.N., Tong M. et al. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naive prostate cancer. Front Oncol 2013;3:293. DOI: 10.3389/fonc.2013.00293.

36. Casamassima F., Masi L., Menichelli C. et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011;97(1):49–55.

37. Napieralska A., Miszczyk L., Tukiendorf A. et al. The results of treatment of prostate cancer bone metastases after CyberKnife radiosurgery. Ortop Traumatol Rehabil 2014;16(3):339–49. DOI: 10.5604/15093492.1112535.

38. Alongi F., Arcangeli S., Filippi A.R. et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012;17(8):1100–7. DOI: 10.1634/ theoncologist.2012-0092.

39. Almaghrabi M.Y., Supiot S., Paris F. et al. Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiat Oncol 2012;7:126. DOI: 10.1186/1748-717X-7-126.

40. Kavanagh B.D., McGarry R.C., Timmerman R.D. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 2006;16(2):77–84.

41. Decaestecker K., De Meerleer G., Lambert B. et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 2014;9:135. DOI: 10.1186/1748-717X-9-135.

42. Ponti E., Ingrosso G., Carosi A. et al. Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience. Clin Genitourin Cancer 2015;13(4):e279–84. DOI: 10.1016/j. clgc.2014.12.014.

43. Ost P., Jereczek-Fossa B.A., As N.V. et al. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatmentnaive Recurrence: A Multi-institutional Analysis. Eur Urol 2016;69(1):9–12. DOI: 10.1016/j.eururo.2015.07.004.

44. Rischke H.C., Schultze-Seemann W., Wieser G. et al. Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 2015;191(4):310–20. DOI: 10.1007/s00066- 014-0763-5.

45. Decaestecker K., De Meerleer G., Ameye F. et al. Surveillance or metastasisdirected Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 2014;14:671. DOI: 10.1186/1471-2407-14-671.

46. Supiot S., Rio E., Pacteau V. et al. OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer 2015;15:646. DOI: 10.1186/s12885-015-1579-0.

47. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castrationresistant prostate cancer. Eur Urol 2014;65(2):467–79. DOI: 10.1016/j.eururo.2013.11.002.